Request Demo

Last update 21 Oct 2026

Dronabinol

Last update 21 Oct 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(-)-delta9-trans-Tetrahydrocannabinol, 1-trans-delta-9-Tetrahydrocannabinol, 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol

+ [40]

Target

Action

agonists

Mechanism

CB agonists(Cannabinoid receptor agonists)

Therapeutic Areas

Other DiseasesNervous System DiseasesDigestive System Disorders+ [5]

Active Indication

AnorexiaNauseaVomiting+ [13]

Inactive Indication

Depressive DisorderMultiple SclerosisTourette Syndrome

Originator Organization

AbbVie, Inc.

Active Organization

Avicanna, Inc.

Tetra Bio-Pharma, Inc.

RespireRx Pharmaceuticals, Inc.

+ [8]

Inactive Organization

Unimed Pharmaceutical, Inc.

Solvay SA

SciSparc Ltd.

+ [1]

License Organization

IntelGenx Corp.

Alkem Laboratories Ltd.

DanCann Pharma A/S

+ [6]

Drug Highest PhaseApproved

First Approval Date

United States (31 May 1985),

AnorexiaNauseaVomiting

RegulationBreakthrough Therapy (United States), Orphan Drug (United States)

Structure/Sequence

Molecular FormulaC21H30O2

InChIKeyCYQFCXCEBYINGO-IAGOWNOFSA-N

CAS Registry1972-08-3

376

Clinical Trials associated with Dronabinol

NCT05432284

/ Not yet recruitingPhase 1IIT

Behavioral Pharmacology of THC and Beta-Myrcene

This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.

Start Date01 Jul 2027

Sponsor / Collaborator

The Johns Hopkins University

[+1]

NCT07224698

/ Not yet recruitingPhase 2IIT

Phase 2 Multicenter Randomized Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of Inhaled Cannabis in Veterans for Treatment of Posttraumatic Stress Disorder (PTSD)

The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.

Start Date01 Feb 2027

Sponsor / Collaborator

Multidisciplinary Association for Psychedelic Studies

ACTRN12620000847910

/ Not yet recruitingPhase 1/2

Safety and Effect of Medical Cannabis on Relapse among 20 Patients with Methamphetamine Use Disorder: A Proof-of-Concept Trial

Start Date01 Dec 2026

Sponsor / Collaborator

University of Edith Cowan

100 Clinical Results associated with Dronabinol

100 Translational Medicine associated with Dronabinol

100 Patents (Medical) associated with Dronabinol

12,094

Literatures (Medical) associated with Dronabinol

01 Feb 2027·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Tracing the roots of illicit Cannabis: A machine learning-assisted ATR-FTIR proof-of-concept study for geographical origin classification

Article

Author: Singh, Mahan ; Sharma, Vishal ; Sharma, Akanksha

Cannabis remains one of the most commonly trafficked and seized illicit drugs around the globe. The growing number of cannabis seizures has created an increasing demand for analytical methods able to determine the geographical origin of seized material rapidly and reliably. Existing approaches are often destructive, require extensive sample preparation, and have limited applicability to Indian cannabis. To address these limitations, the present study explored Fourier-transform infrared spectroscopy in attenuated total reflectance sampling mode (ATR-FTIR) combined with machine learning (ML) approaches for the geographical classification of cannabis samples collected from North India. A total of 200 female cannabis flower-top samples were collected from four distinct geographical regions and 1000 spectral observations were recorded using ATR-FTIR spectroscopy. The spectra obtained presented characteristic absorption bands related to cannabinoids, flavonoids, cellulose, hemicellulose, lignin, and other phytochemical constituents. Then, dataset was reduced using principal component analysis (PCA) and subsequently used to train four ML models. Among the models evaluated, the artificial neural network (ANN) exhibited the best classification performance during the training phase. Its reliability was further validated internally using test data and externally using unknown data. Further, PC3 was the most contributing component to the classification across all models and was associated with holocellulose, lignin, pectin, THCA, and THC. The proposed work has a strong potential for forensic investigations, especially for drug trafficking and identification of cannabis origin in illicit market.

31 Dec 2026·PLATELETS

Pilot study on cannabis-induced alterations in platelet function: implications for transfusion medicine

Article

Author: Loubaki, Lionel ; Cognasse, Fabrice ; Hamzeh-Cognasse, Hind ; Laflamme, Geneviève

Platelet transfusions are essential in the management of thrombocytopenia, bleeding disorders, and hematologic malignancies. With cannabis use rising worldwide, its impact on donor platelet quality and transfusion efficacy remains poorly understood. This study investigated the effects of cannabis joint extracts (CJE) on platelet activation, pro-coagulant phenotype, mitochondrial function, and cytokine/chemokine release, with implications for transfusion safety. Human platelets were exposed in vitro to increasing concentrations of two CJE with distinct cannabinoid profiles: Orchid (O-CJE, THC 10.4%, CBD 14.7%) and QCGold (G-CJE, THC 25.5%, CBD 0.04%). Platelet activation (CD62P, Annexin V), mitochondrial depolarization, ATP levels, aggregation responses, and cytokine secretion (CCL3, PF4) were assessed. RBC lysate experiments were performed to assess the role of hemolysis. The involvement of CB1 and CB2 receptors was tested using specific antagonists, and activation of p38 MAPK and NF-κB pathways was evaluated. Functional effects of platelet supernatants were examined on EA.hy926 endothelial cells. CJE exposure induced dose-dependent platelet activation, characterized by increased CD62P expression, Annexin V binding, mitochondrial depolarization, and ATP depletion, consistent with metabolic stress. Platelet aggregation in response to ADP, collagen, and arachidonic acid was impaired, suggesting a pre-activated or refractory phenotype. RBC lysate did not reproduce the observed effects, indicating hemolysis is unlikely to be the underlying mechanism. CBR1 and CBR2 antagonists did not attenuate platelet activation, while signaling analysis revealed activation of p38 MAPK and NF-κB pathways. Exploratory proteomics indicated modulation of proteins involved in angiogenesis, cytoskeletal organization, and stress responses. Elevated plasma levels of CCL3 and PF4 and endothelial activation (IL-6 secretion, CD54, CD62P, CD62E expression) further suggested a pro-inflammatory environment. Cannabis exposure can alter platelet phenotype and signaling under in vitro conditions, potentially affecting platelet function and interactions with the vascular endothelium. However, these findings require confirmation in vivo to determine their clinical relevance. Future studies should aim to establish exposure thresholds and clarify whether cannabis use has implications for transfusion safety, given potential risks of reduced efficacy or increased thrombotic complications in recipients.

01 Dec 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Application of liquid chromatography with tandem mass spectrometry detection for the determination of twelve cannabinoids in a feasibility study to produce a pharmacologically active ingredient from seized Cannabis sativa L. (marijuana)

Article

Author: de Cassia Mariotti, Kristiane ; de Oliveira Camargo, Flavio Anastacio ; Pereira, Danilo ; Ortiz, Rafael Scorsatto

The increasing demand for Cannabis-derived medicinal products in Brazil, coupled with the implementation of RDC 1013/2026 (ANVISA), necessitates robust analytical frameworks for pharmacological and forensic purposes. This study is part of the "Paracelsus Project," a feasibility study evaluating the production of plant-based active pharmaceutical ingredients (API) from seized Cannabis sativa L. (marijuana), aiming to repurpose material that is currently incinerated. Preliminary data suggests this seized material contained a total of roughly 25 tons of CBD. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous determination of twelve phytocannabinoids (CBD, D9-THC, D8-THC, CBC, CBL, CBN, CBG, THCV, CBDV, CBDVA, CBGA, and THCA). The methodology utilized a triple quadrupole (QQQ) analyzer in positive ionization mode, designed to overcome the challenges of complex plant matrices and chemical isomers. The method achieved successful baseline separation of critical pairs, such as CBD/CBG and D9-THC/D8-THC, in under eight minutes. This analytical workflow was successfully applied to monitor cannabinoid concentrations during the extraction and purification processes from seized marijuana by Brazilian Federal Police. The validated LC-MS/MS method provides the necessary sensitivity and specificity for both quality control in API production and forensic standardization. By establishing a technical foundation for characterizing medicinal extracts and ensuring compliance with the 0.3% THC statutory threshold, this research supports public health safety and the potential for a sustainable pharmaceutical supply chain from seized materials in Brazil.

651

News (Medical) associated with Dronabinol

20 Oct 2026

·www.prnewswire.com

Rare Cannabinoid Company Publishes Expanded CBN vs. CBD Sleep Guide Featuring Human Research

Updated guide explores falling asleep, nighttime awakenings and next-day fatigue, plus melatonin-free CBN sleep gummies and oils with and without THC HONOLULU, Oct. 20, 2026 /PRNewswire/ -- What is the difference between CBN and CBD for sleep? Can nighttime cannabinoids support restful sleep without added melatonin? Rare Cannabinoid Company answers these questions in its substantially expanded CBN vs. CBD for sleep guide. The guide explains human sleep research in plain language and helps readers compare cannabinoid amounts, product formats and melatonin-free nighttime options. Continue Reading Rare Cannabinoid Company’s melatonin-free CBN Sleep Gummies contain 30 mg CBN and 10 mg CBD per gummy, with zero THC, and are featured in its expanded CBN vs. CBD sleep guide. The updated resource introduces CBN, or cannabinol, as a sleep-focused cannabinoid and CBD, or cannabidiol, as a popular ingredient for calm and relaxation. The guide compares three melatonin-free nighttime formulas: a pure CBN oil, CBN sleep gummies with CBD, and CBN-and-CBD gummies with added THC. Key takeaways from the expanded guide Human CBN research offers encouraging sleep findings: Trials have reported fewer nighttime awakenings and, at a higher studied dose, faster sleep onset. Next-day experience matters: A seven-night trial found reduced nighttime awakenings without increased daytime fatigue. Nighttime formulas offer different experiences: Consumers can choose CBN alone, paired with CBD, or combined with CBD and THC. Melatonin is a separate ingredient: Rare Cannabinoid Company's nighttime products contain no added melatonin. Human research brings CBN sleep benefits into focus A randomized, double-blind, placebo-controlled trial published in Experimental and Clinical Psychopharmacology in 2024 analyzed 293 adults with poor self-rated sleep. Participants receiving 20 mg CBN experienced significantly fewer nighttime awakenings and less overall sleep disturbance than those receiving placebo, without increased daytime fatigue. A 2026 sleep-laboratory trial adds encouraging findings on falling asleep. Published in the August 2026 issue of Journal of Sleep Research , the randomized crossover study compared CBN with placebo in 20 adults. A single 300 mg CBN dose helped participants fall asleep faster and improved their perceived sleep quality on secondary measures. The study's main measure—time awake after initially falling asleep—did not significantly change. The guide explains the research dose and how it differs from the amounts in retail products. Explore melatonin-free CBN oils and gummies The guide compares three Rare Cannabinoid Company nighttime formulas: CBN Rest Oil : A sugar-free, flavorless formula containing 500 mg CBN per bottle in certified organic MCT coconut oil, without THC. CBN Sleep Gummies : Each vegan, huckleberry-flavored gummy contains 30 mg CBN and 10 mg CBD, with zero THC. THC + CBN Sleep Gummies : Each vegan, huckleberry-flavored gummy contains 30 mg CBN, 10 mg CBD and 5 mg hemp-derived delta-9 THC. All three contain no added melatonin. Clearly labeled cannabinoid amounts and accessible batch reports help consumers compare ingredients and formats. The research discussed in the guide examined study preparations rather than these finished products. CBN vs. CBD: common questions answered: What is the difference between CBN and CBD? CBN and CBD are separate cannabinoids found in hemp and cannabis. CBN is increasingly studied for sleep and commonly featured in nighttime products. CBD is widely used for calm and relaxation during the day or evening. Can CBN and CBD be taken together? Yes. Combined formulas provide both cannabinoids in one measured serving. Consumers can also choose pure CBN oil when they prefer a simpler formula. Does a CBN product have to contain THC? No. CBN can be formulated without THC. For adults who enjoy THC's dreamy, euphoric effects, THC-containing options offer a different nighttime experience. THC can cause intoxication. Is CBN the same as melatonin? No. CBN is a cannabinoid; melatonin is a hormone involved in sleep-wake timing. Checking the complete ingredients helps consumers distinguish cannabinoid formulas from products that also contain added melatonin. Readers can explore Rare Cannabinoid Company's CBN sleep gummies and oils to compare nighttime options with and without THC. About Rare Cannabinoid Company Rare Cannabinoid Company is a Honolulu-based hemp wellness brand specializing in rare cannabinoids, including CBN, CBG, CBC, THCV and CBDV. Its range includes gummies, oil tinctures and topicals, with clearly labeled cannabinoid amounts and third-party laboratory reports. SOURCE Rare Cannabinoid Company 21% more press release views with Request a Demo

16 Oct 2026

·avicanna.com

Avicanna Transitions US Listing to OTCQB

TORONTO, October 16, 2026 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces that in the US, the Company will transition to OTCQB effective October 16, 2026. About Avicanna: Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in the commercialization of more than fifty finished products. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto™ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. SOURCE Avicanna Inc.  Stay Connected  For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com.  Cautionary Note Regarding Forward-Looking Information and Statements This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

15 Oct 2026

·www.globenewswire.com

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies. Building on its previously announced decision on July 27, 2026 to target the Agentic AI market and the announcement on August 26, 2026 of the establishment of its Scientific Advisory Board for AI and Cybersecurity, the Company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, with a focus on applications such as in cybersecurity and finance technologies. Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks to achieve defined objectives. SciSparc aims to build on its scientific and technical foundation to identify opportunities in these markets and assess potential avenues for establishing its presence in the sector. The Company will continue to evaluate opportunities in the field as it pursues its strategic shift. There can be no assurance that these efforts will result in any transaction, commercial agreement or revenue-generating activity for the Company. About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses its planned shift in strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies; its intention to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem; its aim to build on its scientific and technical foundation to identify opportunities in these markets and assess potential avenues for establishing its presence in the sector; and its plans to continue evaluating opportunities as it pursues its strategic shift. The Company may ultimately not identify any opportunities in the agentic AI field and may not ultimately realize the opportunities contemplated by its strategic shift into the field. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

100 Deals associated with Dronabinol

External Link

KEGG	Wiki	ATC	Drug Bank
D00306	Dronabinol	A04AD10	DB00470

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anorexia	United States	Alkem Laboratories Ltd.	31 May 1985
Nausea	United States	Alkem Laboratories Ltd.	31 May 1985
Vomiting	United States	Alkem Laboratories Ltd.	31 May 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chemotherapy-induced nausea and vomiting	NDA/BLA	Canada	Tetra Bio-Pharma, Inc.	01 May 2023
Lumbosacral Radiculopathy	Phase 3	United States	Vertanical GmbH	22 Sep 2026
Agitation in Dementia	Phase 3	Australia	Benuvia Therapeutics, Inc.	01 May 2026
Alzheimer Disease	Phase 3	Australia	Benuvia Therapeutics, Inc.	01 May 2026
Sleep Apnea, Obstructive	Phase 3	United States	RespireRx Pharmaceuticals, Inc.	01 Feb 2023
Low Back Pain	Phase 3	Germany	Vertanical GmbH	07 Jul 2021
Decrease in appetite	Phase 3	Europe	Solvay SA	15 Feb 2007
Diabetic peripheral neuropathic pain	Phase 3	United States	Vertanical GmbH	-
Osteoarthritis	Phase 3	United States	Vertanical GmbH	-
Osteoarthritis	Phase 3	Canada	Avicanna, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03984214 (ESMO2026)	Phase 3	Pancreatic Cancer First line	104	dronabinol	mwalnbrqyx(gsbvihldtc) = wdktpbajfo ddartttkyn (hmbcafaoid ) View more	Negative	23 Oct 2026
				placebo	mwalnbrqyx(gsbvihldtc) = pilqkzwtuc ddartttkyn (hmbcafaoid ) View more
NCT04448808 (Pubmed \| Nat Med)	Phase 2	Stress Disorders, Post-Traumatic	171	Dronabinol (2.5-15 mg)	nkyafdkqki(quviyphjmz) = xdkrgqrnue rbbbchtiwn (ublihlcilf ) View more	Positive	01 Sep 2026
				Placebo	nkyafdkqki(quviyphjmz) = jeynpxykmx rbbbchtiwn (ublihlcilf ) View more
NCT03106363 (CTgov)	Not Applicable	Psychomotor Disorders	49	alcohol+delta 9 tetrahydrocannabinol (Active Alcohol/Active Cannabis)	llaucfrdkf(ctzdlsywht) = texrbxhilw xfnkeqsyks (ysacookdhk, gmsucvegzg - hrwdatrxnq) View more	-	24 Jul 2026
				placebo alcohol+delta 9 tetrahydrocannabinol (Placebo Alcohol/Active Cannabis)	llaucfrdkf(ctzdlsywht) = xifbhjxgmh xfnkeqsyks (ysacookdhk, mjrncpfrgi - ovxbxafosn) View more
NCT06471647 (ETS, CTgov)	Early Phase 1	Stress, Psychological \| Thrombocytopenia 1	36	Placebo (Placebo)	tderhyifrk(fazydhjgej) = ayxjeosjdc jujadzjvee (uuojmjhtqt, 6.6) View more	-	09 Jul 2026
				THC (5 mg Delta-9-tetrahydrocannabinol (THC))	tderhyifrk(fazydhjgej) = wphvhqyimn jujadzjvee (uuojmjhtqt, 6.5) View more
NCT03661892 (Pubmed \| Oncologist)	Phase 2	Ostealgia	14	Dronabinol 10 mg	sheoghwkdu(mefrsmcfvg) = dizziness hwzwpqacoj (agbiaufgse ) View more	Positive	08 Jul 2026
ASCO2026	Not Applicable	Neoplastic Processes	26	naproxen	yecjdtrxyr(zdexqjcnhr) = khmzlgwtuz vyonswefzz (ifptwiigdl, 82.2 - 90.0)	Positive	29 May 2026
				indomethacin	yecjdtrxyr(zdexqjcnhr) = zqjgjskrea vyonswefzz (ifptwiigdl, 70.5 - 87.5)
NCT02983773 (CTgov)	Phase 2	Marijuana Abuse	157	Placebo (Placebo)	snyfeahkxe(yiuxhkwqgt) = gbqnahyygg dersncsgrm (vbmfvuleex, 1.01) View more	-	21 Apr 2026
				THC 7.2% (7.2% THC)	xgwudycghe(fvybjnzaue) = tttyuxfieb yrzgvdqbkc (jimponikvo, 2.33) View more
NCT04734080 (CTgov)	Phase 4	-	114	Dronabinol 5mg Cap (Dronabinol)	buyjjbqavc(eoewoqhdca) = lkqxbpizmo ozegkqcymi (andhvpgsrj, pwtzggzjum - zwvwxldslw) View more	-	27 Mar 2026
				Placebo oral tablet (Placebo)	buyjjbqavc(eoewoqhdca) = zhbjhasxih ozegkqcymi (andhvpgsrj, wjkzdxgobu - wbwdtvveuy) View more
NCT04360044 (Pubmed \| Headache)	Phase 2	Migraine Disorders	92	6% Δ9-tetrahydrocannabinol (THC)	gjxmefpfmm(abzmigeitb) = vxxanrbmvl infdbscctp (tuvtxfxqab ) View more	Positive	01 Feb 2026
				6% THC + 11% CBD	gjxmefpfmm(abzmigeitb) = phrtigzurh infdbscctp (tuvtxfxqab ) View more
NCT02983773 (Pubmed \| Am J Psychiatry)	Phase 2	Alcoholism	138	Cannabis cigarettes containing 7.2% THC	nrndctxcqu(osuzmewpul) = 7.2% THC reduced alcohol urge immediately after smoking. canknxyfsn (rvqtpihpln )	Positive	01 Feb 2026
				Cannabis cigarettes containing 3.1% THC

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis